Cingulate Inc. (CING)
NASDAQ: CING · Real-Time Price · USD
4.147
+0.227 (5.78%)
Oct 1, 2025, 3:19 PM EDT - Market open

Company Description

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States.

The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials.

It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults.

Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

Cingulate Inc.
Cingulate logo
CountryUnited States
Founded2012
IPO DateDec 8, 2021
IndustryBiotechnology
SectorHealthcare
Employees13
CEOJennifer Callahan

Contact Details

Address:
1901 West 47th Place
Kansas City, Kansas 66205
United States
Phone913 942 2300
Websitecingulate.com

Stock Details

Ticker SymbolCING
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$6.00
CIK Code0001862150
CUSIP Number17248W105
ISIN NumberUS17248W3034
Employer ID86-3825535
SIC Code2834

Key Executives

NamePosition
Dr. Shane J. Schaffer Pharm.D.Co-Founder, Chief Executive Officer and Chairman of the Board (Leave of Absence)
Jennifer L. Callahan CPAInterim Chief Executive Officer, Senior Vice President, Chief Financial Officer and Secretary
John A. Roberts M.B.A.Executive Chairman
Dr. Raul R. Silva M.D.Co-Founder, Executive Vice President and Chief Science Officer
Dr. Matthew N. Brams M.D.Co-Founder, Executive Vice President and Chief Medical Officer
Thomas DaltonVice President of Investor and Public Relations
Nilay Patel J.D.Chief Legal Officer

Latest SEC Filings

DateTypeTitle
Sep 25, 20258-KCurrent Report
Sep 5, 20258-KCurrent Report
Aug 28, 20258-KCurrent Report
Aug 19, 202510-QQuarterly Report
Aug 19, 20258-KCurrent Report
Aug 15, 2025DEF 14AOther definitive proxy statements
Aug 15, 2025NT 10-QNotification of inability to timely file Form 10-Q or 10-QSB
Aug 15, 20258-KCurrent Report
Aug 8, 20258-KCurrent Report
Aug 6, 20258-KCurrent Report